asco 2023 oral presentation guidelines

ASCO Connection

The professional networking site for asco's worldwide oncology community, search form, 2023 asco annual meeting preview: the oncology meeting you can’t miss.

Apr 13, 2023

Find Your Place in the World's Leading Oncology Community 

• Stay current on the most cutting-edge science, therapies, and technologies across disease sites. 
• Notable opportunities to participate in career development, interactive sessions, compelling speakers, and inspirational and reinvigorating discussions. 
• Networking and learning through 5 days of session content, 3 days of posters and exhibits, all with one memorable trip to Chicago.  
• Connections with respected leaders in oncology that can lead to future research collaborations and career opportunities.  
• Over 200 sessions available in-person and on-demand, including 122 hours of livestream content from 64 sessions, from which you can curate your own practice-changing experience. 
• Join livestream sessions from anywhere. 
• Take notes and download slides. 
• Pose questions to speakers. 
• Answer case-based session polls during sessions. 
• View posters and author recordings. 
• Access on demand session videos, slides, and transcripts (available as soon as six hours after each live session). 
• Claim continuing medical education (CME) credit for participation in each session. 
• Adolescent and Young Adult (AYA) Community of Practice—Friday, June 2, 1-3 PM (CT) 
• Geriatric Oncology Community of Practice—Saturday, June 3, 8-9 AM (CT) 
• International Medical Graduates (IMG) Community of Practice—Friday, June 2, 4-6 PM (CT) 
• Medical Educators Community of Practice—Saturday, June 3, 7:30-9:30 AM (CT) 
• Palliative Care Community of Practice—Friday, June 2, 4-6 PM (CT) 

Session Highlights

• Plenary Session, featuring presentation and discussion of the top clinical abstracts of the year. 
• 24 Oral Abstract Sessions and 14 Clinical Science Symposia, featuring over 250 oral abstract presentations. 
• Over 2,000 posters presented in Poster Sessions on Saturday, Sunday, and Monday, including Trials in Progress. Following each track’s poster session, join the Poster Discussion Sessions to hear more discussant commentary on the top 12 posters and Q&A with the authors.  
• New: Rapid Abstract Sessions in Breast Cancer, Developmental Therapeutics – Immunotherapy, and Lung Cancer. 
• Highlights of the Day Sessions on Sunday, Monday, and Tuesday mornings, as well as online. 
• Meet the Professors: Innovations for Hereditary Cancer Syndromes—Cancer Screening and Cascade Testing 
• Meet the Professors: Nuts and Bolts—Building a Needs Assessment Toolkit for Survivorship 
• Extending the Patient Legacy: Rapid Tissue Donation Programs and Their Impact on Cancer Discovery 
• Fireside Chat: International Collaborations to Take Us ALL Into the Future—What Might Childhood ALL Therapy Look Like in 25 Years? 
• Rational Combinations: The Road to Personalized Immunotherapy 
• Integrating Liquid Biopsies Into Patient Care and Clinical Trial Design 
• Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development 
• CAR T-Related Toxicities: Everything Clinicians Need to Know  
• Next-Generation ADCs: Past, Present, and Future 
• The Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between 
• Next-Generation Approaches to Immuno-oncology in Gastrointestinal Cancers: Beyond Checkpoint Inhibitors 
• A Patient’s Journey From Early-Stage to Metastatic Lung Cancer  
• Shared Decision-Making for Older Adults With Cancer Using Available Treatment Tools 
• Managing Cancer Risk in Transgender Patients With Inherited Cancer Predisposition 
• Germline Testing Around the Globe: Challenges in Different Practice Settings 
• Addressing Grief, Burnout, and Well-Being in the Practice of Oncology 

Connecting to our Humanity in Medicine

• Practicing in a Polarized Society: Ethics and Social Justice in Oncology 
• Workshop: Building Partnership During Challenging Conversations With Patients (in-person only) 
• When the World Becomes a Waiting Room: Setting Boundaries With Our Patients and Ourselves 
• Cancer During Pregnancy: Medical, Psychosocial, Ethical, and Legal Considerations 
• Building an Impactful Oncology Care Team With Aligning Incentives 
• “The Long Road to Equity: Life in Cancer Alley” by Rajasree Pia Chowdry, MD  
• “Partnering With Patients for Modern Clinical Trials” by Shalaan Beg, MD, MS 
• “Everything Happens for a Reason” by Anthony D’Amico, MD, PhD 
• “There Is No Cancer Lottery” by Samantha Siegel, MD 
• “If You Want to Go Fast, Go Alone; If You Want to Go Far, Go Together” by Michael Serzan, MD 
• Career Connections: This new space offers seating areas for informal networking and meetings, panel discussions on career development topics, mock interviews and one-on-one mentoring sessions, and the ASCO Career Fair.  
• ASCO Garden: Enjoy the view by Lake Michigan on the D2 terrace. Wine and beer are available for purchase in the afternoon. 
• Find a Colleague directory: Send a direct, private email to connect with both in-person and online attendees. 
• Lakeside Lounge: Relax, recharge, grab a bite to eat, and connect with colleagues. 
• Networking Tables: Reserve a table at the meeting so you know when and where to meet with colleagues (reservations are free and available onsite). 
• Southside Library: A quiet setting to network, charge devices, and grab a coffee or quick bite, while reading available ASCO publications. 
• Medical Student and Resident Abstract Forum: Support the next generation of oncology leaders and explore the research that physicians-in-training are conducting across the globe. 
• Publications Lounge: Meet the editors-in-chief of ASCO journals and catch up on the latest practice-changing research in global oncology. 
• Trainee and Early Career Oncologist Member Lounge: Seek career advice and network with peers and experienced professionals in the field. 
• Women’s Networking Center: Connect with other women in oncology and sign up for individual mentoring sessions. 
• #ASCO23 TweetUp: Meet and mingle with attendees interested in the intersection of oncology and social media. All are welcome, even if you are not active on Twitter. 
• Oncology Division Chiefs’ and Department Chairs’ Breakfast: Network and share best practices pertinent to department and division leaders in oncology. 
• Training Program Directors’ Breakfast: Network, share best practices, and get refreshed on ASCO resources pertinent to fellowship training and oncology training programs. 
• Patient Advocate Lounge: Gather with fellow patient advocates to take a break, grab breakfast and lunch, peruse patient education materials, and attend special sessions.  
• ASCO Annual Business Meeting: ASCO members will hear Society and Association updates and meet incoming ASCO leaders. 

Onsite Amenities And Support 

Experience asco23 online, are you ready for asco23 .

• Look over the program at meetings.asco.org and begin planning your schedule. 
• Use the Find a Colleague directory to send a private direct message to other registered attendees and make plans to meet or catch up. 
• Make sure you’re following ASCO and the meeting hashtag #ASCO23 on your preferred social media apps. 
• May 25 at 5:00 PM (ET): View the majority of the 2023 abstracts ; Late-Breaking Abstracts (LBAs) will be released on a rolling basis during the meeting. 
• Review all the ASCO23 sessions and save sessions you want to attend . Test your login to make sure you can access sessions online when the meeting begins. 
• Review the latest information about onsite amenities you might need , like childcare, nursing rooms, interpreter services, transportation options, and more. 
• Check out the ASCO Educational Book for articles written by Education Program faculty. 
• Access point-of-session–based tools like polling, eQ&A, note-taking, and to claim credits. 
• Explore the Exhibit Hall, where you’ll find Exhibits, Posters, the Industry Expert Theater, Innovation Zone, and food courts. 
• Show your ASCO pride: Purchase ASCO merchandise at the ASCO Store and online. 
• Read ASCO Daily News for session coverage and more.
• Visit the new Career Connections space and check out the ASCO Career Fair, attend career development talks, get a free professional headshot, and utilize space for informal networking. 
• Watch on-demand videos of sessions you missed, download posters and slides, and review session transcripts .
• Share what you learned with your colleagues and patients. Direct your patients to the award-winning Cancer.Net Blog for the latest research and oncologist-approved cancer information resources. 
• Submit your meeting feedback form and tell us how we can make the 2024 ASCO Annual Meeting even more valuable for you. 
• Mark your calendar for the 2024 ASCO Annual Meeting: May 31–June 4, 2024, in Chicago, IL! 

Recent Articles

Yes, You Should Attend the 2023 ASCO Annual Meeting

The questions I am challenged to answer are twofold: (1) Should you attend the 2023 ASCO Annual Meeting? (2) If you attend, how is your time best spent?

Most people agree scientific conferences are important venues for cancer researchers and clinicians to share and discuss research findings, exchange ideas and insights, and network for collaboration and career development.

The first question is easily answered: Yes, you should attend the 2023 ASCO Annual Meeting! However, whether this should be in person or virtually is a complex question discussed in detail elsewhere. 1,2

Assuming you’re in Chicago or online, how best should you spend your time? Attending plenary sessions, presidential symposia, and educational programs are almost always a good investment. The challenge is in apportioning your time in specialized scientific sessions. Veterans will recall running between sessions (no easy feat in the McCormick Place; skip the morning gym) to catch presentations of data from the latest phase I and II studies as well as preliminary results from phase III studies. But is this really the best use of your time at the meeting?

The answer depends in large part on the reproducibility and replicability of conclusions of the studies you listen to. As such, it’s reasonable to review the scorecard. How many phase I and especially phase II studies that claim feasibility or encouraging preliminary results make it to phase III? What proportion of phase III studies are published in a peer-reviewed journal? And, lastly, what proportion of published phase III studies are validated?

From Presentation to Publication

These questions are addressed in many articles. For example, about one-third of 768 presentations at meetings of British surgical societies were published within 2 years of presentation. 3 Success rates of oral presentations were about twice that of poster presentations. The average impact factor—a measure of the frequency with which a journal’s articles are cited—of journals where successful abstracts were published was about 3, and 95% were in journals with an impact factor of less than 6.

I suggest selecting a few scientific presentations of high quality focused on your field of interest. Use your remaining time to think critically about the presentations you attend. — ROBERT PETER GALE, MD, PhD Tweet this quote

Our Dutch surgery colleagues did a bit better, with about two-thirds of abstracts making it to publication. 4 Interestingly, there was relatively little difference in the proportion of accepted vs rejected abstracts eventually published. So, take solace if your abstract is rejected; it’s not the end of the world. Everything can be published somewhere.

(Well, almost anything.)

Some readers may be thinking this spotty track record applies to surgery meetings alone. Not so. An analysis of 578 abstracts presented at the 2009 Society of General Internal Medicine Annual Meeting indicated a subsequent publication rate of less than 50%. 5 Unsurprisingly, phase III studies had higher publication rates compared with other study designs, 67% vs 46%. In contrast, studies with positive results were not associated with higher publication rates compared with studies with negative results (odds ratio = 0.89; 95% confidence interval = 0.6–1.31). And there are many other examples.

There is little question that peer review is reasonably successful in identifying high-quality studies for publication. 6,7 However, there are fewer data on the value of peer review of submitted meeting abstracts. One might rightly wonder what the impact of peer review of abstracts has on the probability of subsequent publication. A study of this question using a data set of 702 submitted abstracts reported little predictive validity of peer review and probability of subsequent publication. 8 Others report similar data. 9

What About for Oncologists and Hematologists?

The next caveat for many readers is the illusion discordances between meeting presentations and subsequent publication, which may operate for surgeons and internists but certainly not for oncologists and hematologists. Think again.

Recently, Cucchi et al published data on abstracts presented at the American Society of Hematology (ASH) Annual Meeting & Exposition in 2013, 2014, and 2015. 10 They looked at the likelihood of abstracts reporting positive results of a phase II study advancing to a confirmatory phase III clinical trial. The authors’ analyzed 292 abstracts covering diverse hematologic cancers where the abstract characterized the results as “encouraging, promising, could represent a novel therapeutic option, or warrants investigation in a randomized trial.” (Sound familiar?) Although 82% of these abstracts were subsequently published, besting our surgery and internal medicine colleagues, most publications reflected the abstract content, often with the same foggy conclusion. The triumph of hope over reason perhaps. Of note, less than 50% of positive studies advanced to a phase III study.

In a literature review of new drugs for acute myeloid leukemia, the authors found very few entered clinical practice. (A prior study estimated the success rate at less 5%. 11 ) I’m unaware of similar analyses of publication of abstracts presented at the ASCO Annual Meeting, but this should be done. Results are likely to be similar to those reported for the ASH Annual Meeting & Exposition.

Troubles with reproducibility and especially replicability are not limited to meeting abstracts and presentation; they are common in publications in peer-reviewed articles in high–impact factor journals. Ioannidis, Prasad, and colleagues and others have analyzed the reliability of conclusions of these types of articles extensively. 12,13 For example, Ioannidis reviewed 49 highly cited (> 1,000 citations) clinical research studies published in NEJM, JAMA, The Lancet, JNCI, JCO, Blood , and others. A total of 45 claimed the intervention was effective; 7 were contradicted by subsequent studies; 7 others reported effects stronger than observed in subsequent studies; 20 conclusions were replicated; and 11 conclusions were unconfirmed. Five of six highly cited nonrandomized studies reported stronger effects or were contradicted in subsequent analyses vs 9 of 39 randomized controlled trials. Caveat emptor.

Recommended Plan of Action

My advice? First, you should attend the 2023 ASCO Annual Meeting. Whether you do so in person or virtually depends on many considerations. Either way, benefits will be substantial, but some depend on which option you chose. Schmoozing with colleagues in the lobby bar of your hotel is not an option for virtual attendees, but they may benefit from not madly racing around the conference center to catch every potentially interesting presentation, waiting 30 minutes in line to get a venti nonfat latte, or paying $15 for a small glass of pinot noir of uncertain provenance.

A word of caution, especially for junior colleagues and colleagues in training: If you dash around trying to catch every potentially interesting presentation at the meeting, much of what you will hear, especially the results of phase I and II studies, is unlikely ever to be published in a peer-reviewed journal, advance to a phase III study, and even less likely to enter clinical practice. That is the case even when the presenter describes the results as “encouraging, promising, could represent a novel therapeutic option, or warrants investigation in a randomized trial”—or words to that effect to quote lawyers. In fact, some of what you hear is likely to be wrong and set your thinking back rather than forward.

I suggest selecting a few scientific presentations of high quality focused on your field of interest. Use your remaining time to think critically about the presentations you attend. The best outcome, of course, is to grab the presenter after the session and torture him/her with questions. Remember, good scientists look for evidence that their hypotheses are wrong, not right.

What else to do if you go to the meeting? Enjoy chatting with mentors, colleagues, and friends. See Chicago, one of our most important cities architecturally, home of the first skyscrapers (see the Monadnock Building, those of Mies van der Rohe, the Willis Tower nee Sears Tower [how the mighty have fallen], and several Frank Lloyd Wright homes like the Robie House), a boat trip on the Chicago River, and dinner at Topolobampo, probably the best Mexican restaurant in the United States (why is it in Chicago?). See you soon at the 2023 ASCO Annual Meeting. 

DISCLOSURE: Dr. Gale has received research support from the UK National Institute of Health Research funding scheme.

1. Sarabipour S, Khan A, Seah YFS, et al: Changing scientific meetings for the better. Nat Hum Behav 5:296-300, 2021.

2. Wallon G, Bendiscioli, Asif A, et al: The values of scientific conferences in a virtual framework: Analysis and practical options. Available at chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.embo.org/documents/courses_and_workshops/reports/values_of_scientific_conferences_in_a_virtual_framework_report.pdf. Accessed July 5, 2022.

3. Weale AR, Edwards AG, Lear PA, et al: From meeting presentation to peer-review publication: A UK review. Ann R Coll Surg Engl 88:52-56, 2006.

4. de Meijer VE, Knops SP, van Dongen JA, et al: The fate of research abstracts submitted to a national surgical conference: A cross-sectional study to assess scientific impact. Am J Surg 211:166-171, 2016.

5. Egloff HM, West CP, Wang AT, et al: Publication rates of abstracts presented at the Society of General Internal Medicine Annual Meeting. J Gen Intern Med 32:673-678, 2017.

6. Bornmann L, Daniel HD: The usefulness of peer review for selecting manuscripts for publication: A utility analysis taking as an example a high-impact journal. PLoS One 5:e11344, 2010.

7. Jackson JL, Srinivasan M, Rea J, et al: The validity of peer review in a general medicine journal. PLoS One 6:e22475, 2011.

8. Scholcoff, C, Sanghani, P, Jackson W, et al: Peer review of abstracts submitted to an internal medicine national meeting: Is it a predictor of future publication? J Gen Intern Med 33:1002-1003, 2018.

9. Deveugele M, Silverman J: Peer-review for selection of oral presentations for conferences: Are we reliable? June 2017. Patient Education and Counseling 100:2147-2150, 2017.

10. Cucchi DGJ, Polak TB, Ossenkoppele GJ, et al: The predictive value of a positive phase 2 ASH abstract for peer-reviewed publication and progression to phase 3. Blood 139:1920-1923, 2022.

11. Walter RB, Appelbaum FR, Tallman MS, et al: Shortcomings in the clinical evaluation of new drugs: Acute myeloid leukemia as paradigm. Blood 116:2420-2428, 2010.

12. Prasad VK, Cifu AS: Ending Medical Reversals: Improving Outcomes, Saving Lives. Baltimore, MD: Johns Hopkins University Press; 2015.

13. Ioannidis JP: Contradicted and initially stronger effects in highly cited clinical research. JAMA 294:218-228, 2005.

Dr. Gale is Visiting Professor of Haematology at Imperial College London and a Foreign Member of the Russian Federation and China Academies of Science and Medical Science. Photo courtesy of Patricia Williams.

Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer

Professional societies introduce new evidence-based guidelines on testing immunotherapy biomarkers in nsclc, accelerated aging may be a risk factor for early-onset cancers in younger generations, novel mdm2 inhibitor shows activity in salivary gland cancers, novel spect/ct imaging technique under study in prostate cancer.

• Editorial Board
• Advertising
• Disclosures
• Privacy Policy

Search form

Asco family of sites.

• ASCO Connection
• ASCO Daily News
• ASCO Journals
• ASCO Practice Central
• ASCO Education
• Cancer.Net - For Patients
• Conquer Cancer
• TAPUR Study
• The ASCO Post

ASCOconnection.org features blogs from members, the online version of the membership magazine, a discussion area, working groups, and links to the Membership Directory, Career Center, and Volunteer Portal.

ASCO Daily News is the official conference reporter for ASCO meetings and symposia, providing high-quality, unbiased research summaries and oncology news to members and oncology health care providers.

ASCO’s growing roster of cutting-edge journals serves readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe.

ASCO Practice Central helps oncology professionals navigate a complicated and ever-changing practice environment—while providing high-quality patient care.

Stay updated on the latest oncology has to offer with ASCO Education—your online, on-demand resource for timely information, real-world application, and practice-changing care.

A cutting-edge health information technology platform, CancerLinQ® enables practitioners to learn from individual patients. By assembling vast amounts of usable, searchable, real-world data, CancerLinQ seeks to improve the quality and value of cancer care.

Cancer.Net brings the expertise and resources of ASCO to people living with cancer and those who care for and about them to help patients and families make informed health care decisions.

Conquer Cancer, the ASCO Foundation, raises funds to support the world's leading researchers who are improving treatments and discovering cures for every cancer, every patient, everywhere.

ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial aiming to describe the performance of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer with a potentially actionable genomic variant.

The ASCO Post, in partnership with the American Society of Clinical Oncology, communicates news of the highest quality multidisciplinary cancer care to a broad audience of oncology professionals and members.

News Releases

Additional noteworthy studies to be presented during 2023 asco annual meeting.

ALEXANDRIA, Va. – Twenty studies exploring a wide range of topics across many cancer disease sites will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL, and online, June 2-6.

ASCO Experts in multiple disease areas are available to provide outside commentary and perspective on the studies below. Contact the ASCO Media Team to schedule an interview.

Abstract LBA506: 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). Abstract presentation part of session beginning at 2:45 p.m. CT on Friday, June 2. “Among chemotherapy-free patients treated with trastuzumab and pertuzumab (group B with PET response and pathologic complete response), three-year invasive disease-free survival was 98.8%. This strategy identifies about one in three patients with HER2[+] early-breast cancer who can safely omit chemotherapy with significantly reduced toxicity,” said lead study author Javier Cortes.

Abstract 5015: A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Abstract presentation part of session beginning at 8:00 a.m. CT on Saturday, June 3.

Abstract LBA100: KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early-stage NSCLC Please note: The full abstract will not be publicly available until 7:00 a.m. CT on June 3 and is embargoed until that time. Credentialed reporters can use the embargoed abstract search tool to view beforehand. Abstract presentation part of session beginning at 8:00 a.m. CT on Saturday, June 3. “These results indicate the peri-operative pembrolizumab given in combination with chemotherapy prior to surgery and for up to one year as a single agent after surgery led to significant improvement in event-free survival (defined by local progression precluding definitive surgery, recurrence, or death) with a strong trend towards improvement in overall survival.  These results indicate peri-operative pembrolizumab significantly improves outcomes for patients with potentially resectable stage II-III NSCLC,” said lead study author Heather Wakelee, MD, FASCO.

Abstract 5503: Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). Abstract presentation part of session beginning at 3:00 p.m. CT on Saturday, June 3. "The results from the RUBY trial mark a milestone in the treatment of advanced or recurrent, mismatch repair deficient endometrial cancer. The addition of dostarlimab to the standard regimen of paclitaxel and carboplatin resulted in a drastic reduction in the risk of disease progression. Given the rising incidence and mortality of endometrial cancer, particularly among minority women, this finding represents a significant and transformational advancement,” said ASCO Expert Kathleen Moore, MD, MS.

Abstract 6509: Strategies to increase accrual of underrepresented populations in Alliance NCTN trials. Abstract presentation part of session beginning at 1:15 p.m. CT on Saturday, June 3. “Using a multi-pronged approach to increase accrual of racial and ethnic minority patients with cancer to clinical trials, the Alliance for Clinical Trials Network achieved a substantial increase in participation. This overwhelmingly successful approach not only reiterates the efficacy of multi-pronged approaches but also underscores that inclusivity in clinical research can be easily integrated into most clinical trial settings,” said Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO.

“Intentional approaches to increase the accrual of underrepresented minorities (URM) to Alliance trials resulted in increased accrual from 13.6% to 25.3% for treatment and 13% to 21.5% for cancer control trials during 2018-2023. This reflects an overall increase from 13.5 % to 23.6% of URMs for all trials, a 74.8% improvement. With more diversity in clinical trials, we can make the results of trials representative of (and applicable to) all patients,” said lead study author Electra D. Paskett, PhD.

Abstract 4023: Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial. Abstract presentation part of session beginning at 11:30 a.m. CT on Monday, June 5. “We found that for resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria, neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX regimen could result in satisfactory objective response rates and disease control rates, and could also significantly improve the overall and recurrence-free survival of patients compared to direct surgery. This result means that neoadjuvant hepatic arterial infusion chemotherapy can be an effective and safe approach to bring better prognosis for this group of patients who have been previously considered to have limited benefit from surgery and provides evidence for more relevant studies in the future,” said lead study author Wei Wei, MD, PhD.

“The results of this phase III study show that combining neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX can lead to improved progression-free and overall survival and has minimal complications for patients with early-stage resectable hepatocellular carcinoma (HCC). These findings have the potential to change how we treat HCC, offering new options for patients, a significant step toward improving outcomes and redefining the standard of care,” said ASCO Expert Glenn Hanna, MD.

Abstract LBA5000: Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2x2 design. Please note: The full abstract will not be publicly available until 7:00 a.m. CT on June 4 and is embargoed until that time. Credentialed reporters can use the embargoed abstract search tool to view beforehand. Abstract presentation part of session beginning at 8:00 a.m. CT on Sunday, June 4. "The phase III PEACE-1 trial yielded valuable insights, confirming the results of previous trials such as HORAD and STAMPEDE, that radiation to the prostate does not improve overall survival in patients with de novo, low-volume, metastatic, castration-sensitive prostate cancer. However, the best outcomes were observed when radiation was alongside the standard of care and abiraterone. This suggests that the role of radiation, while not definitive in overall survival, may still be an important element in a more comprehensive, personalized treatment approach,” said ASCO Expert Bradley McGregor, MD.

Abstract 1501: Large-scale observational prospective cohort study of a multi-cancer early detection (MCED) test in symptomatic patients referred for cancer investigation. Abstract presentation part of session beginning at 1:15 p.m. CT on Saturday, June 3. “The test could speed up the diagnostic process for patients with symptoms of cancer by focusing cancer investigations on the cancer site of origin, identifying patients not usually referred for cancer investigation, and reducing unnecessary referrals for cancer investigation.,” said lead study author Associate Professor Brian D. Nicholson.

"The results of this study highlight the current limitations of blood testing for ctDNA in diagnosing occult cancer. While the concept of enhanced screening is appealing, the technology is still in its early developmental stages, lacking the necessary accuracy and clinical utility to benefit patients and providers. Despite its non-invasive nature, the ctDNA assay examined in this study falls short in terms of sensitivity and predictive value, rendering it unsuitable for diagnostic purposes. Further research and refinement are essential before this test can be considered a valuable tool in detecting hidden cancers,” said ASCO Expert Erica Mayer, MD, MPH.

Abstract LBA3503: Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. Please note: The full abstract will not be publicly available until 7:00 a.m. CT on June 4 and is embargoed until that time. Credentialed reporters can use the embargoed abstract search tool to view beforehand. Abstract presentation part of session beginning at 8:00 a.m. CT on Sunday, June 4. “We found no difference in the effect from neoadjuvant chemotherapy followed by surgery compared to the standard upfront surgery followed by adjuvant chemotherapy in patients with locally advanced colon cancer. Neoadjuvant chemotherapy is a safe treatment compared to upfront surgery. Taken together with the newly published results from the FOxTROT trial, patients now have a real choice between the traditional upfront surgery and neoadjuvant chemotherapy. Effect and safety is at least as favorable, and patient preference can be included in the individual treatment plan,” said lead study author Lars Henrik Jensen, MD, PhD.

Abstract 10001: Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial. Abstract presentation part of session beginning at 9:45 a.m. CT on Sunday, June 4. "The RIST trial’s findings underline the significant impact of adding dasatanib and rapamycin to the standard irinotecan and temozolomide treatment for high-risk, relapsed or refractory neuroblastoma. Not only was progression-free survival doubled in an intention-to-treat analysis, but overall survival was extended, particularly among the mycn+ cohort, without adding extra toxicity. This method offers a promising new salvage regimen for this high-risk disease,” said ASCO Expert Heather Symons, MD, MHS

Abstract 8510: Preliminary results from the Female Asian Nonsmoker Screening Study (FANSS). Abstract presentation part of session beginning at 11:30 a.m. CT on Monday, June 5. “Preliminary results from the Female Asian Nonsmoker Screening Study demonstrate that a lung cancer screening program in a population that does not smoke cigarettes is feasible. Although we are reporting on small numbers thus far, our study shows an early snapshot of a lung cancer detection rate of 1.5% which appears to be on par with what has been seen in a large-scale screening study conducted for nonsmokers in Taiwan. Expanding lung cancer screening to other populations beyond those who smoke cigarettes, such as those who do not smoke, are warranted given increased treatment options in the early-stage lung cancer setting, such as the approval of adjuvant osimertinib from the ADAURA study. We hope this study will help to address the need for screening efforts in those who do not smoke, as many are unfortunately diagnosed with stage IV lung cancer due to lack of screening,” said lead study author Elaine Shum, MD.

Abstract 12015: Effect of flibanserin on libido in women with breast cancer on adjuvant endocrine therapy. Abstract presentation part of session beginning at 1:15 p.m. CT on Monday, June 5. “While we continue to make strides in the treatment of breast cancer, the side effects, especially sexual dysfunction in younger women, often remain unaddressed in the clinical setting. This study offers an insight into the role of flibanserin in tackling this sensitive but common issue, showing an improvement in sexual dysfunction in patients taking the medication. Although the findings are based on a small cohort, they serve as a catalyst for a larger, robust, and comprehensive study to further examine the potential of this agent in improving the overall well-being of breast cancer patients,” said ASCO Expert Erica Mayer, MD, MPH.

Abstract 6009: Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). Abstract presentation part of session beginning at 1:15 p.m. CT on Monday, June 5. “The prespecified final overall survival analysis of JUPITER-02 study showed that the addition of toripalimab to chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma provided significantly better and clinically meaningful improvement in overall survival than chemotherapy alone, independent of PD-L1 expression status. The addition of toripalimab to first-line chemotherapy reduced the chance of death by 37% than chemotherapy alone and improved the three-year survival rate to 64.5%. Toripalimab plus gemcitabine-cisplatin chemotherapy represents a new standard of care for this patient population,” said lead study author Haiqiang Mai.

Abstract LBA107: Primary overall survival analysis of the phase 3 randomized ZUMA‑7 study of axicabtagene ciloleucel versus standard‑of‑care therapy in relapsed/refractory large B-cell lymphoma. Please note: The full abstract will not be publicly available until 7:00 a.m. CT on June 5 and is embargoed until that time. Credentialed reporters can use the embargoed abstract search tool to view beforehand. Abstract presentation part of session beginning at 9:45 a.m. CT on Monday, June 5. “In a randomized global phase 3 trial, we found that patients with refractory or early relapsed large B-cell lymphoma who were treated with axi-cel, a CAR T-cell therapy, as second-line treatment had a 27.4% reduction in the risk of death compared with the previous standard of chemotherapy and stem cell transplant. The results of the Primary Overall Survival Analysis of the ZUMA-7 trial mean that more patients live longer with second-line axi-cel compared with the previous standard of care, and that axi-cel should be a second-line treatment instead of trying chemotherapy first and saving CAR T-cell therapy for patients who do not respond. We believe our data represent a paradigm shift, and mean that patients should be referred to a CAR T-cell center for an evaluation before starting chemotherapy,” said lead study author Jason Westin, MD, MS, FACP.

Abstract 4508: SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer. Abstract presentation part of session beginning at 11:30 a.m. CT on Monday, June 5.

Abstract 10027: Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study. Abstract presentation part of session beginning at 8:00 a.m. CT on Sunday, June 4. "The KEYNOTE-667 study reveals that for children and young adults who have Hodgkin lymphoma and a slow early response to chemotherapy, adding pembrolizumab as consolidation and maintenance therapy is a promising strategy. By augmenting responses and sparing the need for radiation, it holds potential in mitigating relapse risks, though we acknowledge further follow-up is necessary to establish its long-term efficacy,” said ASCO Expert Melissa Hudson, MD.

Abstract LBA9000: Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. Please note: The full abstract will not be publicly available until 7:00 a.m. CT on June 6 and is embargoed. Credentialed reporters can use the embargoed abstract search tool to view beforehand. Abstract presentation part of session beginning at 9:45 a.m. CT on Tuesday, June 6. “The findings of the KEYNOTE-789 study have significant implications for clinical practice. Many community oncologists had generalized the results of the Keynote 189 trial to all patient populations, but this study clearly demonstrates that chemo-immunotherapy is not suitable for EGFR+ NSCLC patients after progression on osimertinib. Immediate changes in patient care are necessary to avoid unnecessary toxicity and focus on more effective treatment strategies,” said ASCO Expert Jyoti D. Patel, MD.

ASCO Research to be Presented During 2023 ASCO Annual Meeting

Abstract 3115: Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Abstract presentation part of session beginning at 8:00 a.m. CT on Saturday, June 3. “ASCO’s TAPUR Study results reveal talazoparib as a potential treatment option beyond its current FDA-approved indications, showing strong responses and disease control in heavily pretreated patients with various cancers with BRCA1/2 mutations. If these findings are confirmed in larger studies, this could mean a new treatment avenue for patients with hard-to-treat diseases that lack effective options. Further validation through larger studies is essential to confirm these promising findings,” said lead author Gordan Srkalovic, MD.

Abstract 3117: Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Abstract presentation part of session beginning at 8:00 a.m. CT on Saturday, June 3. “Part of ASCO’s TAPUR study, these cohorts evaluated the role of temsirolimus in patients with PIK3CA-mutated advanced solid tumors, shedding light on the potential use of this targeted therapy in other cancers. While the disease control rate in patients with breast cancer was not significant, it was 29% for those with other solid tumors, with a remarkable response seen particularly in a patient with heavily pretreated ovarian cancer with otherwise poor prognosis. These results underscore the importance of comprehensive molecular testing, such as next-generation sequencing, which can yield new treatment opportunities for patients,” said lead study author Carmen Calfa, MD.

Abstract 5548: Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Abstract presentation part of session beginning at 1:15 p.m. CT on Monday, June 5. “The combination therapy of nivolumab and ipilimumab achieved a disease control rate of 27% in patients with recurrent ovarian cancer and BRCA1/2 mutations in the ASCO TAPUR study. Although the criteria for antitumor activity were not met overall, the observation of partial responses, with some lasting over 62 weeks, supports further investigation into predictive biomarkers for response to this treatment combination,” said lead study author Charles Drescher, MD.

View the disclosures for the 2023 Cancer Communications Committee: https://old-prod.asco.org/sites/new-www.asco.org/files/content-files/about-asco/pdf/2023-AM-CCC-Disclosures.pdf

View the disclosures for Dr. Gralow

ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL COVERAGE.

About ASCO :  

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org , explore patient education resources at www.Cancer.Net , and follow us on Facebook, Twitter, LinkedIn, and YouTube.

Related News Releases

Related tags.

• Meetings News
• Events Calendar /calendar Events Calendar
• Research & Data ASCO Journals TAPUR Study CDK4/6 Inhibitor Dosing Knowledge (CDK) Study Clinical Trials ASCO Data Library Reports & Studies Research Survey Pool Interactive Map of Oncology /research-data Research & Data
• Guidelines /practice-patients/guidelines Guidelines
• Grants & Awards /career-development/grants-awards Grants & Awards
• Cancer Progress Timeline /news-initiatives/cancer-progress-timeline Cancer Progress Timeline
• Volunteering & Committees Apply to Volunteer FASCO Distinction International Cancer Corps Policies for Volunteers & Committee Members Regional Councils /get-involved/volunteering-committees/volunteer-asco Volunteering & Committees
• Discussion Groups https://myconnection.asco.org Discussion Groups

CASE REPORT article

Case report: a case of recurrent cervical cancer with bronchial and esophageal metastases presenting with hemoptysis and dysphagia.

• 1 Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, China
• 2 Medical College, Qingdao University, Qingdao, China

Background: The treatment outcomes and prognosis for recurrent cervical cancer are generally poor, with a 5-year survival rate of only 10%–20%.

Case presentation: In this case, the patient is a young woman who experienced a recurrence 5 years after the initial treatment of cervical cancer. Her primary symptoms were hemoptysis and dysphagia, indicative of hilar and mediastinal lymph node metastases, with further involvement of the bronchus and esophagus. Additionally, the patient also presented with tumor-associated dermatomyositis. Following combined treatment with albumin-bound paclitaxel, carboplatin, bevacizumab, and cadonilimab, the patient’s tumor was effectively controlled.

Case presentation

A 39-year-old young woman was hospitalized in December 2016 due to persistent vaginal bleeding for 1 month. The admission diagnosis was human papillomavirus (HPV)-related cervical cancer (IB1, G2), according to the International Federation of Gynecology and Obstetrics (FIGO) 2009. The patient underwent laparoscopic radical hysterectomy, bilateral salpingectomy, pelvic lymphadenectomy, and bilateral ovarian transposition. Postoperative pathology revealed moderately differentiated squamous cell carcinoma of the cervix, with deep one-third of the cervical stroma infiltrated, lymphovascular space invasion (LVSI) positive, and no pelvic lymph node metastasis. According to the Sedlis criteria, pelvic external radiation therapy along with concurrent chemoradiotherapy was performed. The patient’s postoperative follow-up showed no abnormalities in 57 months.

In September 2021, the patient developed irregular edematous erythema on the trunk and limbs, with visible vesicles and ruptures. She consulted the Rheumatology and Immunology Department and was diagnosed with dermatomyositis (DM). After symptomatic treatments, the patient’s DM was stably controlled, followed by oral administration of prednisone acetate, 10 mg daily, for maintenance therapy. Meanwhile, she returned to the outpatient clinic for follow-up, and no recurrence of cervical cancer was detected.

In August 2022, the patient presented with symptoms of dysphagia, hoarseness, chest tightness, shortness of breath, coughing, and bloody sputum. Physical examination revealed red rashes and scattered vesicles on both upper arms, the back, and around both knee joints. Routine gynecological examination showed no abnormalities. Transcription intermediary factor 1-gamma (TIF1-γ) antibody was positive. Tumor marker screening indicated an elevated squamous cell carcinoma (SCC) antigen level of 45.06 ng/mL. Enhanced CT scans revealed partial stenosis and obstruction of the right upper lobe bronchus. Narrowing of the bilateral main bronchi and multiple enlarged lymph nodes in the hilum and mediastinum were observed. The middle segment of the esophagus (at the T5–T7 level) showed localized wall thickening with luminal stenosis and dilatation of the esophagus above ( Figures 1A, B ). Bronchoscopic examination revealed a narrowing of the openings of the bilateral main bronchi and a narrowing of the lumen of the left main bronchus with easily bleeding mucosa ( Figure 1C ). Pathological examination through bronchoscopy revealed squamous epithelial nests in the bronchial mucosa tissue. Based on morphology, immunohistochemistry results, and history, metastatic squamous cell carcinoma, likely originating from cervical cancer, was considered. Immunohistochemistry showed p16 (+), CK5/6 (+), p40 (partially +), and PD-L1-22C3 (tumor proportion score (TPS): −) ( Figure 2 ). During gastroscopy, circumferential stenosis was observed at 30 cm from the incisors, preventing the passage of the endoscope, with the esophageal mucosa appearing smooth ( Figure 1D ). Barium meal examination showed localized esophageal luminal stenosis of approximately 38 mm, with dilation above the stenosis ( Figure 3A ). Based on these findings, recurrent cervical cancer with secondary malignant tumors in the bronchus, esophagus, and mediastinum accompanied by tumor-associated DM was confirmed.

Figure 1 Patient’s chest CT, bronchoscopy, and gastroscopy examination. (A) The arrow indicates the narrowed left main bronchus. (B) The arrow indicates the narrowed esophagus. (C) Bronchoscopy shows narrowing of the left main bronchus with white necrotic material attached. (D) Gastroscopy shows circumferential narrowing of the esophagus with smooth mucosa.

Figure 2 Patient’s bronchial biopsy pathology. (A) Bronchial biopsy pathology (H&E staining, ×100). (B) Strong positive expression of P16 (immunohistochemistry staining, ×100).

Figure 3 Comparison of barium swallow radiography before and after treatment. (A) Before treatment, localized narrowing of the esophageal lumen, involving an area of approximately 38 mm, with dilation above the narrowed segment. (B) After treatment, the local esophageal wall mucosa appears slightly irregular.

Following a multidisciplinary consultation involving the Departments of Gynecology, Oncology, Rheumatology and Immunology, and Radiology, the patient was considered to have an extra-pelvic recurrence of cervical cancer with concomitant tumor-associated DM. It was recommended to treat the DM while also initiating anti-tumor therapy. According to the 2022 cervical cancer National Comprehensive Cancer Network (NCCN) guidelines, the preferred systemic treatment for recurrent or metastatic cervical cancer is paclitaxel + cisplatin/carboplatin ± bevacizumab ± pembrolizumab (for PD-L1-positive patients). Given the patient’s recurrence of cervical cancer involving the trachea and esophagus, presenting with symptoms, like hemoptysis and dysphagia, and concurrent autoimmune disease DM, to reduce the use of steroid medication and to avoid gastrointestinal reactions caused by cisplatin, the patient was administered intravenous chemotherapy with albumin-bound paclitaxel (210 mg/m 2 ) + carboplatin [area under the curve (AUC) = 5] every 3 weeks for a total of three cycles. After improvement in hemoptysis, bevacizumab (7.5 kg/m 2 ) was added for two cycles. During chemotherapy, the patient’s SCC antigen levels initially decreased and then fluctuated and increased ( Figure 4 ). After five cycles of chemotherapy, the radiological evaluation in February 2023 showed similarity to before chemotherapy treatment. Due to acute esophageal obstruction, gastroscopy was performed, confirming persistent esophageal stenosis.

Figure 4 SCC antigen levels during treatment and observation (reference range 0–2.5 ng/mL). SCC, squamous cell carcinoma.

After completing five cycles of chemotherapy, the patient’s therapeutic evaluation indicated stable disease (SD). Her DM remained stable. Following a multidisciplinary discussion, a decision was made to adjust the treatment plan to include “albumin-bound paclitaxel + carboplatin + bevacizumab (7.5 mg/kg) + cadonilimab (10 mg/kg)”, with the schedule set for five consecutive cycles (one cycle every 3 weeks). The patient’s hemoptysis, dysphagia, hoarseness, and other discomfort were completely relieved, and the SCC antigen levels decreased significantly. After undergoing 10 cycles of chemotherapy post-recurrence, radiological assessment in July 2023 showed apparent slight stenosis in the right upper lobe bronchus, a slight narrowing of the bilateral main bronchi, no significant enlargement of lymph nodes in the hilum and mediastinum, and local wall thickening in the mid-segment of the esophagus (at the T5–T7 level) with apparent slight stenosis in some pulmonary bronchi. Barium meal examination showed localized esophageal wall mucosa appears slightly irregular ( Figure 3B ). The patient’s tumor was well-controlled, and she was given maintenance therapy with bevacizumab (7.5 mg/kg) + cadonilimab (10 mg/kg). However, in October 2023, the patient’s DM worsened, leading to the cessation of maintenance therapy, and she was temporarily under observation. During this period, follow-up indicated an increase in SCC antigen levels from 1.98 ng/mL to 3.49 ng/mL, although radiological assessment did not reveal any tumorous lesions. A consultation with a radiation oncologist was required to consider radiation therapy to the mediastinal lymph node drainage areas. Treatment timeline for patient was shown in ( Figure 5 ).

Figure 5 Treatment timeline for patient. DM, dermatomyositis; SD, stable disease; PR, partial response; SCC, squamous cell carcinoma antigen; PD, progressive disease.

Approximately 30% of cervical cancer patients experience tumor recurrence or metastasis after initial treatment, with most recurrences occurring within 2 years post-treatment and fewer cases after 5 years ( 1 ). Recurrences can be categorized into intra-pelvic and extra-pelvic. Treatment for recurrent and metastatic cervical cancer is challenging, and prognosis is poor, with a 5-year survival rate of only 10%–20%, making it a difficult aspect of gynecologic oncology ( 2 ). The patient, in this case, a young woman, underwent surgery and concurrent chemoradiotherapy in 2016 for stage IB1 cervical cancer. She experienced a recurrence 5 years post-initial treatment, with no signs of pelvic recurrence. The presentation was an unusual extra-pelvic recurrence, primarily manifesting as hemoptysis and dysphagia, involving the bronchus and esophagus. The lung metastasis in this patient was not a parenchymal spread but involved the bronchial walls; the esophagus was also considered to be narrowed due to the tumor. The bronchial and esophageal changes were attributed to the invasion of surrounding tissues due to metastases to the pulmonary hilum and mediastinal lymph nodes. Literature indicates that the mediastinal metastasis rate for cervical cancer is approximately 1%, and with the continuous development of techniques such as PET-CT and endoscopic ultrasound-guided fine-needle aspiration, mediastinal metastasis can be more definitively diagnosed ( 3 ). While the incidence of lung metastases is approximately 20%–50%, bronchial metastases are rare, accounting for less than 5% ( 4 ). Distinguishing between primary and metastatic bronchial tumors in pathology morphology is challenging. In this case, the patient’s bronchial biopsy pathology revealed squamous cell carcinoma with a strong positive expression of P16 for immunohistochemistry staining. Considering the history, this was deemed a recurrence and metastasis of cervical cancer. The patient’s recurrence site was special and extensive, limiting radiation and surgical treatment. Considering the potential tissue fibrosis and difficult improvement in esophageal stenosis caused by radiation, the treatment choice was primarily systemic therapy.

The PD-L1 positivity rate in cervical cancer patients ranges from approximately 34.4% to 96% ( 5 , 6 ), making immune checkpoint inhibitors (ICIs) a novel strategy for treating recurrent or metastatic cervical cancer. The 2022 cervical cancer NCCN guidelines list paclitaxel + cisplatin/carboplatin ± bevacizumab ± pembrolizumab (applicable for PD-L1-positive patients) as the preferred systemic treatment for recurrent or metastatic cervical cancer ( 7 , 8 ). For this patient, who was PD-L1 negative and also suffering from tumor-associated DM, with initial symptoms of hemoptysis and dysphagia, we opted for a chemotherapy regimen of albumin-bound paclitaxel combined with carboplatin. After the patient’s hemoptysis symptoms improved, we added the anti-angiogenic drug bevacizumab. Following the initial chemotherapy, the patient’s tumor marker SCC antigen levels significantly decreased but fluctuated and increased. After completing five cycles of chemotherapy, the radiological assessment indicated SD. After multidisciplinary discussions and a thorough evaluation of the risks and benefits of using ICIs, we decided to add cadonilimab (a PD-1/CTLA-4 dual-target antibody). The AK104-201 study, a multicenter, open-label Phase 1b/II clinical trial conducted in China, included 111 patients with recurrent/metastatic cervical cancer who had previously received platinum-based chemotherapy but failed treatment. Of these, 100 patients were treated with cadonilimab and included in the efficacy analysis, showing an overall response rate (ORR) of 33%, with PD-L1-positive patients [combined positive score (CPS) ≥ 1] at 43.8% and PD-L1-negative patients at 16.7%. The study demonstrated that patients could benefit from cadonilimab treatment regardless of PD-L1 expression status ( 9 , 10 ). The Chinese Society of Clinical Oncology (CSCO) guidelines recommend the use of cadonilimab in recurrent or metastatic cervical cancer, particularly for PD-L1-negative patients. In this case, we administered five cycles of cadonilimab treatment to the patient, resulting in significant improvement of the tumor and full relief of symptoms such as dysphagia and hoarseness, leading to the cessation of chemotherapy and entry into the maintenance treatment phase. However, as the patient’s DM worsened, we discontinued ICI treatment. During observation, SCC antigen levels gradually increased, but radiological examinations did not reveal positive findings. Five months after stopping chemotherapy, we decided to administer radiation therapy to the mediastinal drainage area.

Five years after the initial treatment, the patient was diagnosed with DM, and cervical cancer recurrence was confirmed 11 months after the onset of DM. The timing of DM and cancer recurrence was closely aligned. DM is an autoimmune disease primarily affecting the skin and skeletal muscles, with patients having a fivefold increased risk of concurrent malignancy compared to the general population, making it a paraneoplastic syndrome ( 11 ). TIF1-γ antibody is considered a serological marker for malignancy-associated adult DM, with TIF1-γ-positive DM patients having a 38% to 71% probability of concurrent malignancy ( 12 ). In this case, the patient was TIF1-γ positive, and her DM was exacerbated concurrent with the diagnosis of recurrent cervical cancer. The DM symptoms improved as the tumor was controlled, suggesting a tumor-associated DM. Given the patient’s PD-L1-negative status and concurrent autoimmune disease, the use of ICIs required special caution. However, no adverse symptoms emerged post-ICI administration in this patient. With the improvement in dysphagia, her dietary intake normalized, and her general health gradually improved, yielding positive treatment outcomes. Cancer patients with autoimmune diseases are not absolute contraindications for ICIs therapy, and potential risks and benefits must be weighed in clinical applications. According to the 2023 NCCN guidelines, autoimmune disease patients who have not received or only received low-dose immunosuppressive therapy and have controlled disease conditions may consider ICIs therapy ( 7 ). For this patient, we will closely monitor her condition and enhance early detection of adverse drug reactions to maximize therapeutic efficacy.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by the Ethics Committee of the Qingdao University Affiliated Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

XY: Writing – original draft, Methodology, Visualization, Writing – review & editing. SD: Data curation, Writing – original draft. WW: Data curation, Writing – original draft. XS: Data curation, Writing – original draft. YW: Supervision, Writing – original draft. FY: Supervision, Writing – review & editing.

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

1. Li Z, Lin Y, Cheng B, Zhang Q, Cai Y. Prognostic model for predicting overall and cancer-specific survival among patients with cervical squamous cell carcinoma: A SEER based study. Front Oncol . (2021) 11:651975. doi: 10.3389/fonc.2021.651975

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . (2021) 71:209–49. doi: 10.3322/caac.21660

3. Kiryu T, Hoshi H, Matsui E, Iwata H, Kokubo M, Shimokawa K, et al. Endotracheal/endobronchial metastases: clinicopathologic study with special reference to developmental modes. Chest . (2001) 119:768–75. doi: 10.1378/chest.119.3.768

4. Marchioni A, Lasagni A, Busca A, Cavazza A, Agostini L, Migaldi M, et al. Endobronchial metastasis: an epidemiologic and clinicopathologic study of 174 consecutive cases. Lung Cancer . (2014) 84:222–8. doi: 10.1016/j.lungcan.2014.03.005

5. Enwere EK, Kornaga EN, Dean M, Koulis TA, Phan T, Kalantarian M, et al. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol . (2017) 30:577–86. doi: 10.1038/modpathol.2016.221

6. Grau-Bejar JF, Garcia-Duran C, Garcia-Illescas D, Mirallas O, Oaknin A. Advances in immunotherapy for cervical cancer. Ther Adv Med Oncol . (2023) 15:17588359231163836. doi: 10.1177/17588359231163836

7. Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, et al. NCCN guidelines(R) insights: cervical cancer, version 1.2024. J Natl Compr Canc Netw . (2023) 21:1224–33. doi: 10.6004/jnccn.2023.0062

8. Borcoman E, Le Tourneau C. Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer. Ann Transl Med . (2020) 8:1611. doi: 10.21037/atm-20-2656

9. Pang X, Huang Z, Zhong T, Zhang P, ZM W, Xia M, et al. Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. MAbs . (2023) 15:2180794. doi: 10.1080/19420862.2023.2180794

10. Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial. Lancet Oncol . (2023) 24:1134–46. doi: 10.1016/S1470-2045(23)00411-4

11. Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of Malignancy in dermatomyositis and polymyositis. J Cutan Med Surg . (2017) 21:131–6. doi: 10.1177/1203475416665601

12. Kim Y, Song KS, Sohn EH, Kang SW, Yoo IS, Shim SC, et al. Anti-TIF1gamma antibody and the expression of TIF1gamma in idiopathic inflammatory myopathies. Int J Rheum Dis . (2019) 22:314–20. doi: 10.1111/1756-185X.13424

Keywords: recurrent cervical cancer, bronchial metastasis, esophageal metastasis, immune checkpoint inhibitor, tumor-associated dermatomyositis

Citation: Yu X, Dong S, Wang W, Sun X, Wang Y and Yu F (2024) Case report: A case of recurrent cervical cancer with bronchial and esophageal metastases presenting with hemoptysis and dysphagia. Front. Oncol. 14:1375035. doi: 10.3389/fonc.2024.1375035

Received: 23 January 2024; Accepted: 01 April 2024; Published: 19 April 2024.

Reviewed by:

Copyright © 2024 Yu, Dong, Wang, Sun, Wang and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yankui Wang, [email protected] ; Fengsheng Yu, [email protected]

† These authors have contributed equally to this work

‡ ORCID : Yankui Wang, orcid.org/0000-0001-6161-8304 , Fengsheng Yu, orcid.org/0000-0002-3227-8627

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.